The item has been added to your shopping cart.
Home » Australian Panel Questions Cost of Vertex’s Combination Treatment for Cystic Fibrosis
Australian Panel Questions Cost of Vertex’s Combination Treatment for Cystic Fibrosis
An Australian healthcare costs advisory body has declined to recommend government coverage of Vertex Pharmaceuticals’ Trikafta (elexacaftor/tezacaftor/ivacaftor) as a cystic fibrosis treatment given the expense of the therapy.
Australia’s Pharmaceutical Benefits Advisory Committee said the medicine provided a significant benefit for some patients but that its cost-effectiveness has not been established.
Vertex has pledged to continue working with the committee to bring the combination therapy to patients as soon as possible.
Upcoming Events
-
21Oct